rational
asthma
exacerb
initi
viral
upper
respiratori
ill
unclear
whether
human
rhinoviru
hrv
induc
exacerb
associ
greater
viral
replic
neutrophil
inflamm
compar
hrv
cold
object
evalu
viral
strain
load
prospect
asthma
cohort
natur
cold
method
adult
enrol
first
sign
cold
daili
monitor
symptom
medic
use
peak
expiratori
flow
rate
resolut
serial
nasal
lavag
induc
sputum
sampl
assess
viral
copi
number
inflammatori
cell
count
measur
main
result
total
person
asthma
control
subject
without
atopi
asthma
studi
week
per
subject
averag
particip
develop
asthma
exacerb
detect
hrv
preced
day
common
attribut
exposur
relat
exacerb
compar
infect
minor
group
hrv
like
caus
exacerb
p
overal
sputum
neutrophil
burden
rhinoviru
lower
airway
similar
control
subject
without
atopi
asthma
group
howev
among
hrvinfect
particip
asthma
exacerb
associ
greater
sputum
neutrophil
count
p
conclus
hrv
infect
frequent
caus
exacerb
adult
asthma
cold
may
groupspecif
differ
sever
event
absenc
larg
differ
viral
burden
among
group
suggest
differenti
lower
airway
sensit
effect
neutrophil
inflamm
patient
exacerb
continu
controversi
respect
contribut
viral
upper
respiratori
tract
infect
asthma
exacerb
adult
whether
viral
strain
differ
term
associ
lower
airway
burden
likelihood
caus
exacerb
exposur
minor
group
human
rhinovirus
hrv
highest
rate
exacerb
studi
patient
asthma
exacerb
higher
sputum
neutrophil
count
routin
cold
without
larg
differ
hrv
burden
group
acut
asthma
exacerb
remain
signific
caus
morbid
acceler
declin
lung
function
although
symptomat
upper
respiratori
tract
viral
ill
domin
risk
factor
pediatr
exacerb
link
less
well
establish
adult
one
prospect
cohort
adult
patient
asthma
recruit
baselin
follow
year
show
adult
exacerb
preced
upper
respiratori
symptom
adult
asthma
experi
number
cold
domest
partner
without
asthma
twice
like
develop
lower
airway
symptom
numer
studi
enrol
time
exacerb
show
associ
respiratori
virus
wide
rang
detect
time
sampl
acquisit
natur
infect
may
critic
given
intens
cold
symptom
first
day
predict
worsen
asthma
control
cold
score
report
particip
second
day
short
challeng
contribut
incomplet
understand
pathophysiolog
asthma
exacerb
adult
potenti
hinder
develop
effect
treatment
use
specif
asthma
control
threaten
although
virusinduc
asthma
exacerb
frequent
associ
rhinovirus
cold
result
exacerb
highlight
interact
pathogen
host
inocul
studi
laboratori
strain
human
rhinoviru
hrv
demonstr
signific
variabl
host
immun
respons
hrv
infect
although
magnitud
time
respons
relat
overal
inflammatori
profil
resolv
neutrophil
inflamm
lower
airway
demonstr
featur
exacerb
howev
less
attent
paid
molecular
virolog
natur
cold
contribut
acut
asthma
sequenc
analysi
demonstr
hrv
strain
major
hrv
bind
intercellular
adhes
molecul
icam
includ
serogroup
group
b
minor
hrv
small
subset
serogroup
bind
lowdens
lipoprotein
receptor
ldlr
hrvc
describ
recent
appear
bind
either
ldlr
suggest
group
differ
pathogen
hrvc
infect
commonli
found
hospit
children
strain
moreov
sever
studi
shown
lower
airway
infect
rhinoviru
whether
potenti
exist
differenti
strain
evalu
object
studi
determin
relationship
acut
asthma
symptom
hrv
group
lower
airway
viral
burden
set
natur
infect
hypothes
rate
asthma
exacerb
differ
among
hrv
group
lower
airway
viral
burden
drive
acut
neutrophil
inflammatori
respons
correl
acut
asthma
symptom
risk
exacerb
herein
describ
prospect
cohort
patient
asthma
healthi
volunt
recruit
cold
season
enrol
first
onset
natur
occur
upper
respiratori
infect
uri
asthma
symptom
develop
two
poster
abstract
discuss
portion
result
previous
publish
studi
approv
univers
wisconsin
health
scienc
institut
review
board
particip
provid
written
inform
consent
recruit
fall
spring
cold
season
enrol
requir
modifi
jackson
cold
symptom
score
least
previous
describ
figur
show
basic
studi
design
subject
complet
eight
visit
includ
seven
opportun
collect
nasal
lavag
sampl
two
induc
sputa
first
visit
acut
occur
within
first
day
onset
cold
visit
recoveri
period
primarili
nasal
lavag
collect
diari
valid
estim
precold
baselin
state
last
two
visit
resolut
schedul
upper
lower
respiratori
symptom
resolv
detail
regard
particip
entri
criteria
follow
procedur
describ
onlin
supplement
skin
test
aeroallergen
count
lung
function
measur
nasal
lavag
induc
sputum
collect
sampl
process
assess
exhal
nitric
oxid
exacerb
defin
asthma
index
score
greater
previous
describ
onlineavail
worksheet
time
first
exacerb
also
record
event
addit
detail
present
onlin
supplement
nasal
lavag
sputum
rna
sampl
extract
aliquot
cell
pellet
contain
cell
storag
trizol
reagent
invitrogen
carlsbad
ca
revers
transcript
cdna
standard
method
respiratori
multicod
assay
eragen
bioscienc
madison
wi
use
fluorimetr
detect
presenc
common
respiratori
virus
multiplexpolymeras
chain
reaction
pcr
flow
cytometri
sampl
posit
rhinovirus
partial
sequenc
variabl
region
noncod
genom
determin
strain
quantit
pcr
perform
univers
rhinoviru
primer
set
use
abi
prism
machin
appli
biosystem
carlsbad
ca
oligonucleotid
sequenc
primer
follow
pcr
forward
primer
ctagcctgcgtgg
pcr
revers
primer
aaaca
cggacacccaaagtagt
probe
cggcccctgamgbnfq
primer
correspond
conserv
region
untransl
region
valid
hrv
strain
refin
consider
sequenc
field
strain
includ
hrvc
estim
viral
burden
similar
method
describ
previous
hrv
copi
number
determin
extrapol
realtim
pcr
data
standard
curv
gener
stock
known
concentr
term
plaqueform
unit
employ
follow
definit
viral
infect
refer
presenc
viru
least
two
contigu
collect
sampl
viral
ill
infect
occur
conjunct
upper
respiratori
symptom
greater
confid
interv
jackson
symptom
score
report
resolut
visit
virusassoci
exacerb
first
detect
given
viru
strain
occur
within
day
exacerb
day
start
exacerb
anteced
respiratori
sampl
collect
base
data
previou
studi
assum
exacerb
rate
threefold
differ
group
acutetobaselin
chang
sputum
neutrophil
calcul
patient
asthma
would
provid
power
test
hypothesi
uripreced
asthma
exacerb
associ
increas
sputum
neutrophil
compar
patient
asthma
uri
exacerb
primari
analysi
plan
also
includ
comparison
hazard
rate
exacerb
infect
differ
hrv
group
well
comparison
hrv
copi
number
group
particip
asthma
stratifi
exacerb
statu
secondari
endpoint
includ
develop
logist
regress
model
describ
acut
postcold
resolut
factor
predict
exacerb
statu
first
four
visit
see
onlin
supplement
detail
well
comparison
viru
copi
number
neutrophil
count
particip
asthma
collect
valu
obtain
nonatop
nonasthmat
control
group
variabl
fall
normal
distribut
adjust
log
natur
log
squar
root
transform
appropri
statist
analysi
graph
perform
jmp
sa
cari
nc
sigmaplot
sysstat
softwar
san
jose
ca
test
method
comparison
describ
text
p
valu
less
consid
signific
total
volunt
includ
asthma
recruit
cold
season
involv
total
personweek
figur
studi
visit
structur
procedur
particip
recruit
enrol
fall
spring
season
mass
email
radio
newspap
advertis
instruct
present
within
hour
onset
cold
symptom
first
visit
complet
within
day
onset
cold
symptom
vast
major
first
visit
complet
within
day
onset
first
resolut
visit
schedul
cold
acut
lower
airway
symptom
longer
present
seven
nasal
lavag
nl
two
induc
sputum
sampl
collect
shown
similarli
spirometri
exhal
nitric
oxid
feno
methacholin
challeng
test
perform
shown
followup
total
respiratori
sampl
process
viru
detect
histor
data
show
subject
asthma
use
prednison
requir
emerg
depart
visit
hospit
requir
intens
care
asthma
past
total
subject
complet
visit
one
subject
exclud
due
restrict
lung
physiolog
four
analyz
incomplet
diari
data
preclud
calcul
asthma
index
remain
particip
allerg
asthma
nonatop
asthma
tabl
distribut
age
sex
differ
studi
complet
statu
anova
p
chisquar
p
respect
unfortun
despit
similar
ill
sever
nonwhit
particip
time
like
withdraw
prematur
studi
result
studi
popul
white
chisquar
p
nonetheless
incid
prior
prednison
burst
advanc
medic
care
differ
asthma
particip
complet
withdraw
studi
complet
withdraw
chisquar
p
particip
cold
symptom
score
day
enrol
peak
acut
score
higher
individu
baselin
averag
p
comparison
rate
viral
infect
high
differ
among
subject
group
tabl
total
patient
asthma
control
subject
infect
rhinoviru
studi
distribut
rhinoviru
serotyp
group
shown
tabl
virus
detect
patient
asthma
control
subject
includ
coronaviru
n
respiratori
syncyti
viru
b
n
total
particip
virus
detect
nasal
lavag
sampl
collect
first
two
visit
also
viru
present
sputum
sampl
match
strain
case
compar
upper
lower
respiratori
isol
total
particip
one
infect
usual
separ
period
health
absenc
cold
symptom
one
subject
mix
infect
one
viru
strain
respiratori
syncyti
virusb
coronaviru
result
exacerb
final
five
asymptomat
infect
occur
cold
symptom
resolv
hrv
group
distribut
shown
tabl
total
exacerb
occur
cours
studi
subject
geometr
averag
time
first
exacerb
day
onset
cold
figur
show
cold
symptom
score
asthma
index
time
respiratori
sampl
repres
patient
wherea
figur
show
profil
subject
whose
initi
cold
symptom
occur
absenc
viru
detect
total
first
exacerb
associ
hrv
first
detect
viru
occur
within
day
exacerb
day
event
anteced
sampl
exist
hrvassoci
exacerb
occur
geometr
mean
day
onset
cold
symptom
compar
day
manifest
nonhrvassoci
exacerb
anova
p
compar
patient
asthma
without
exacerb
differ
lung
function
first
visit
prior
use
inhal
corticosteroid
ic
number
posit
skin
test
tabl
despit
characterist
studi
entri
similar
nonexacerb
particip
asthma
exacerb
time
studi
airflow
obstruct
greater
asthma
index
variabl
resolut
period
see
tabl
onlin
supplement
qualit
detect
rhinoviru
largest
risk
factor
exacerb
logist
regress
model
tabl
find
remain
signific
adjust
preenrol
ic
use
fev
measur
resolut
adjust
confid
interv
p
respect
hrv
group
differ
seven
nine
subject
expos
minor
group
rhinoviru
exacerb
highest
proport
subject
risk
first
event
tabl
hazard
rate
hrv
group
apport
use
followup
time
first
viru
detect
compar
viral
group
environment
exposur
combin
hazard
ratio
exacerb
minor
group
rhinoviru
exposur
p
tabl
peak
nasal
lavag
rhinoviru
copi
number
occur
median
day
selfreport
onset
symptom
interquartil
rang
day
result
similar
find
inocul
studi
geometr
mean
hrv
copi
sputum
sampl
patient
exacerb
numer
higher
exacerb
although
reach
statist
particip
acut
cold
symptom
upon
enrol
asthma
stratifi
presenc
absenc
exacerb
entir
cours
studi
viru
exposur
list
number
subject
group
respiratori
sampl
posit
virus
continu
data
repres
mean
sd
anova
student
test
use
test
continu
data
group
subject
asthma
respect
chisquar
test
present
categor
data
signific
current
sampl
size
versu
copi
p
evalu
whether
individu
higher
burden
hrv
lower
airway
detect
nose
express
data
ratio
sputum
copi
number
maximum
found
nasal
lavag
sampl
particip
figur
demonstr
patient
rhinovirustrigg
asthma
exacerb
like
without
exacerb
sputumtonas
lavag
hrv
ratio
greater
suggest
replic
viru
lower
airway
differ
viral
load
sputum
sampl
among
class
hrv
subject
asthma
exacerb
caus
higher
neutrophil
count
sputum
sampl
collect
acut
visit
particip
without
asthma
exacerb
figur
also
case
restrict
analysi
hrvexpos
individu
geometr
mean
sputum
polymorphonuclear
cell
pmn
higher
patient
exacerb
compar
without
p
estim
influx
pmn
cold
also
evalu
acutetobaselin
ratio
sputum
pmn
univari
logist
regress
analysi
show
everi
twofold
increas
acutetobaselin
sputum
pmn
ratio
odd
ratio
exacerb
confid
interv
p
tabl
final
differ
viral
burden
sputum
neutrophil
count
patient
asthma
control
particip
without
atopi
figur
perform
logist
regress
analysi
data
subject
asthma
test
associ
subject
ill
characterist
asthma
exacerb
tabl
sever
cold
durat
upper
respiratori
symptom
qualit
detect
rhinoviru
neutrophil
influx
associ
exacerb
upon
recoveri
cold
percent
predict
fev
fvc
ratio
variabl
significantli
relat
exacerb
similar
result
obtain
analyz
asthma
index
continu
variabl
data
shown
addit
subject
allerg
asthma
upper
respiratori
symptom
coincid
environment
exposur
relev
allergen
rate
season
symptomat
allergen
exposur
differ
accord
exacerb
statu
p
chang
durat
upper
respiratori
symptom
subject
asthma
versu
without
season
exposur
respect
p
three
subject
exacerb
like
due
alternaria
sensit
exposur
absenc
viru
detect
howev
small
number
patient
group
permit
reliabl
estim
hazard
rate
moreov
neither
chang
sputum
eosinophil
chang
exhal
nitric
oxid
level
predict
exacerb
entir
cohort
see
onlin
supplement
includ
tabl
viral
infect
particip
asthma
time
studi
enumer
group
virus
detect
acut
visit
nearli
present
first
sampl
give
number
first
sampletot
virus
detect
median
durat
viral
shed
day
interquartil
rang
total
subject
viru
detect
subject
subject
experienc
infect
cours
studi
usual
repres
distinct
cold
five
viral
infect
asymptomat
viral
ill
occur
first
exacerb
present
number
exacerb
personweek
followup
associ
hazard
rate
proport
hazard
model
test
differ
individu
hrv
group
final
particip
take
ic
enrol
greater
chang
sputum
eosinophil
trend
toward
higher
sputum
hrv
copi
number
compar
subject
take
ic
figur
contrast
chang
exhal
nitric
oxid
level
differ
accord
presenc
absenc
ic
use
cold
figur
goal
studi
determin
whether
rhinoviru
cold
associ
distinct
pattern
viral
replic
neutrophil
airway
inflamm
subject
asthma
determin
whether
predictor
correl
exacerb
threefourth
cold
studi
due
rhinovirus
hrv
exposur
primari
agent
associ
exacerb
follow
day
rate
higher
end
report
studi
may
part
reflect
recruit
strategi
design
enrol
subject
first
sign
cold
exacerb
occur
data
present
studi
provid
sever
novel
insight
foremost
rate
exacerb
higher
group
minor
hrv
compar
group
combin
may
first
studi
adult
asthma
examin
differ
hrv
group
pathogen
publish
studi
children
suggest
hrvc
may
like
caus
sever
exacerb
requir
hospit
hrvc
difficult
grow
cultur
appear
bind
ldlr
although
perform
broad
surveil
adult
complet
profil
hrv
strain
commun
cold
season
hrv
group
shown
like
increas
symptom
burden
gener
popul
adult
collect
data
suggest
may
age
depend
intens
immun
respons
hrv
prior
exposur
hrvc
may
provid
greater
protect
subsequ
exposur
group
adult
comparison
hrv
group
potenti
mechan
vari
hrv
group
pathogen
warrant
studi
includ
baselin
differ
lower
airway
epitheli
cell
express
level
ldlr
receptor
hrvc
inconsist
effect
ic
express
receptor
andor
potenti
diverg
signal
pathway
lead
product
chemokin
andor
antivir
factor
quantit
assess
hrv
copi
number
associ
lower
airway
inflamm
patient
asthma
rel
control
subject
without
atopi
asthma
also
previous
shown
natur
infect
demonstr
hrv
copi
number
acut
sputum
sampl
patient
asthma
differ
group
accord
exacerb
statu
howev
patient
hrvassoci
exacerb
greater
fivefold
neutrophil
acut
sputum
sampl
subject
hrv
cold
exacerb
data
interpret
sever
way
first
like
variabl
measur
hrv
rna
copi
number
sputum
sampl
greater
associ
neutrophil
enumer
sens
present
studi
may
underpow
detect
differ
lower
airway
hrv
copi
number
would
predict
patient
asthma
inde
rel
defici
antivir
factor
consist
notion
observ
select
patient
exacerb
sputumtopeak
nasal
lavag
hrv
ratio
greater
suggest
lower
airway
replic
light
interest
post
hoc
analysi
show
trend
toward
increas
sputum
hrv
copi
number
patient
previous
take
ic
previou
ic
use
may
marker
attenu
antivir
host
factor
product
similarli
administr
oral
steroid
shown
increas
nasal
hrv
titer
inocul
experi
increas
burden
may
effect
medicin
second
patient
exacerb
could
robust
recruit
andor
delay
clearanc
neutrophil
inflammatori
cell
lower
airway
set
similar
viral
challeng
respect
latter
possibl
defect
alveolar
macrophag
phagocytosi
associ
sever
asthma
phenotyp
exacerb
prone
third
given
control
subject
hrv
infect
nonatop
present
studi
similar
sputum
neutrophil
count
patient
asthma
like
addit
featur
asthmat
lower
airway
contribut
exacerb
phenotyp
collect
observ
need
valid
larger
cohort
goal
identifi
biomark
relat
risk
exacerb
natur
infect
quantit
pcr
perform
use
univers
hrv
primer
avail
acut
sampl
particip
detect
rhinoviru
stratifi
presenc
absenc
exacerb
occur
within
day
collect
sputum
sampl
occur
cold
day
acut
period
sputum
hrv
burden
express
ratio
peak
occur
nl
sampl
chisquar
analysi
done
rate
hrv
copi
sputum
sampl
peak
nl
sampl
size
respect
b
absolut
number
neutrophil
per
gram
sputum
acut
visit
sputum
neutrophil
data
subject
asthma
shown
regardless
viru
detect
n
respect
data
log
transform
anova
test
data
express
box
whisker
plot
clearli
time
respiratori
sampl
collect
critic
natur
infect
studi
design
number
strength
limit
consid
interpret
find
fulli
character
effect
acut
ill
particip
complet
four
studi
visit
within
first
day
onset
cold
symptom
cold
symptom
score
particip
continu
rise
earli
visit
peak
nasal
lavag
hrv
copi
number
occur
third
day
cold
symptom
similar
observ
inocul
experi
lung
function
first
visit
differ
patient
asthma
without
exacerb
suggest
recruit
effort
enrol
preexacerb
popul
nonetheless
possibl
acut
sampl
collect
peak
inflamm
abil
test
multipl
sampl
respiratori
secret
sensit
comprehens
pcrbase
viral
diagnost
add
valid
identifi
viral
ill
furthermor
hrvposit
sampl
confirm
sequenc
molecular
type
allow
analysi
groupspecif
effect
contrast
previou
work
other
identifi
femal
sex
race
peak
expiratori
flow
variabl
lack
use
ic
histori
treatment
oral
corticosteroid
prednison
independ
risk
factor
incid
sever
asthma
exacerb
factor
signific
present
studi
may
reflect
limit
sampl
size
mild
baselin
diseas
impair
note
initi
patient
asthma
requir
prednison
andor
advanc
medic
care
episod
current
studi
demonstr
recruit
strategi
captur
atrisk
popul
entri
criteria
requir
fev
predict
first
visit
absenc
baselin
use
highdos
ic
prednison
ensur
safeti
complex
visit
structur
procedur
burden
find
may
appli
sever
asthma
although
popul
clearli
interest
term
potenti
interact
corticosteroid
viral
burden
use
recent
adapt
nasal
sampl
collect
method
home
may
allow
us
enrol
patient
futur
protocol
greater
spectrum
diseas
sever
fewer
dedic
studi
visit
conclus
show
hrv
infect
frequent
exposur
adult
caus
season
asthma
exacerb
set
concomit
upper
respiratori
symptom
minor
group
hrv
highest
rate
rel
particip
asthma
experienc
hrv
cold
subject
exacerb
higher
sputum
neutrophil
count
increas
chanc
hrv
detect
sputum
compar
nasal
sampl
ongo
work
sever
laboratori
focus
ident
rhinoviru
speci
sequenc
element
confer
pathogen
risk
addit
studi
also
warrant
regard
mechan
allerg
inflamm
influenc
antivir
respons
andor
sensit
lower
airway
injuri
associ
neutrophil
influx
author
disclosur
lcd
receiv
consult
fee
merck
inc
institut
receiv
fund
two
issu
patent
wisconsin
alumni
research
foundat
rl
financi
relationship
commerci
entiti
interest
subject
manuscript
wml
financi
relationship
commerci
entiti
interest
subject
manuscript
mde
financi
relationship
commerci
entiti
interest
subject
manuscript
mjw
financi
relationship
commerci
entiti
interest
subject
manuscript
skm
receiv
consult
fee
cephalon
inc
employ
univers
wisconsin
madison
gmc
financi
relationship
commerci
entiti
interest
subject
manuscript
klg
financi
relationship
commerci
entiti
interest
subject
manuscript
tep
financi
relationship
commerci
entiti
interest
subject
manuscript
rfv
financi
relationship
commerci
entiti
interest
subject
manuscript
eak
financi
relationship
commerci
entiti
interest
subject
manuscript
jeg
receiv
consult
fee
glaxosmithklin
gsk
biota
centocor
synairgen
bioscienc
boehring
ingelheim
stock
option
bioscienc
eragen
bioscienc
institut
receiv
grant
merck
inc
astrazeneca
nnj
institut
receiv
grant
merck
gsk
pharmaxi
genetech
receiv
consult
fee
asthmatx
genetech
gsk
receiv
honorarium
saudi
thorac
societi
gsksupport
continu
medic
educ
program
